Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.48 |
| ▸ | TUBB | P07437 | 3/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055881 | 1.00 | MAPT (0.62) | MAPTATMSMN1; SMN2NPC1KMT2A | |
| SCHEMBL4055724 | 0.87 | NPC1 (0.55) | MAPTATMSMN1; SMN2NPC1KMT2A | |
| SCHEMBL4055727 | 0.87 | NPC1 (0.55) | MAPTATMSMN1; SMN2NPC1KMT2A | |
| SCHEMBL4056642 | 0.83 | NPC1 (0.51) | MAPTATMSMN1; SMN2NPC1KMT2A | |
| SCHEMBL4056638 | 0.83 | NPC1 (0.51) | MAPTATMSMN1; SMN2NPC1KMT2A | |
| SCHEMBL13607768 | 0.77 | TUBB4A (0.54) | MAPTATMSMN1; SMN2NPC1KMT2A | |
| SCHEMBL4060105 | 0.77 | NPC1 (0.45) | MAPTATMSMN1; SMN2NPC1KMT2A | |
| SCHEMBL4060113 | 0.77 | NPC1 (0.45) | MAPTATMSMN1; SMN2NPC1KMT2A | |
| SCHEMBL4059729 | 0.76 | NPC1 (0.44) | MAPTATMSMN1; SMN2NPC1KMT2A | |
| SCHEMBL4059720 | 0.76 | NPC1 (0.44) | MAPTATMSMN1; SMN2NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785499-B2 | Targeting NAD biosynthesis in bacterial pathogens | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-07-26 | — | — | US | disclosed |
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | MAPT 4026/4885ATM 431/4885SMN1; SMN2 4289/4885 |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | NAMPT, NAPRT, NADK | MAPT 1896/4885ATM 3855/4885SMN1; SMN2 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.